CATALOGO DEI PRODOTTI DELLA RICERCA

DE NITTO, SIMONE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.409
EU - Europa 1.751
AS - Asia 1.470
SA - Sud America 191
Continente sconosciuto - Info sul continente non disponibili 106
AF - Africa 64
OC - Oceania 5
Totale 5.996
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.347
RU - Federazione Russa 868
SG - Singapore 639
IT - Italia 278
CN - Cina 272
HK - Hong Kong 159
BR - Brasile 158
VN - Vietnam 144
FR - Francia 105
DE - Germania 99
IE - Irlanda 87
GB - Regno Unito 83
SE - Svezia 70
KR - Corea 66
BD - Bangladesh 65
FI - Finlandia 49
CA - Canada 35
ES - Italia 34
IN - India 26
JP - Giappone 21
TG - Togo 19
PL - Polonia 18
ID - Indonesia 16
BJ - Benin 14
MX - Messico 13
NL - Olanda 10
LT - Lituania 9
NG - Nigeria 9
AR - Argentina 8
IQ - Iraq 8
PH - Filippine 8
VE - Venezuela 8
AT - Austria 7
BE - Belgio 7
UA - Ucraina 7
CO - Colombia 6
TR - Turchia 6
UZ - Uzbekistan 6
ZA - Sudafrica 6
EC - Ecuador 5
IR - Iran 5
MA - Marocco 5
PK - Pakistan 5
AE - Emirati Arabi Uniti 4
AU - Australia 4
PY - Paraguay 4
AZ - Azerbaigian 3
CH - Svizzera 3
CR - Costa Rica 3
JO - Giordania 3
KE - Kenya 3
SA - Arabia Saudita 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
JM - Giamaica 2
KG - Kirghizistan 2
LB - Libano 2
OM - Oman 2
RS - Serbia 2
TN - Tunisia 2
AO - Angola 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
CL - Cile 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
EG - Egitto 1
EU - Europa 1
GE - Georgia 1
GH - Ghana 1
GR - Grecia 1
GT - Guatemala 1
IS - Islanda 1
LK - Sri Lanka 1
LV - Lettonia 1
MG - Madagascar 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PE - Perù 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
RO - Romania 1
SV - El Salvador 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 5.891
Salva come PNG Salva come JPEG
Città #
Singapore 377
Ashburn 360
Dallas 313
San Jose 311
Moscow 264
Chandler 260
Hong Kong 157
The Dalles 111
Council Bluffs 102
Verona 88
Dublin 84
Beijing 62
Ho Chi Minh City 57
Munich 47
Los Angeles 46
Redmond 37
Columbus 33
New York 33
Buffalo 31
Hanoi 30
Milan 30
Lawrence 25
Princeton 25
London 24
Helsinki 23
Madrid 23
Seattle 23
Santa Clara 21
Sindelfingen 20
Lomé 19
Tokyo 19
Wilmington 19
Redondo Beach 18
Seoul 18
Turku 16
Orem 15
São Paulo 15
Cotonou 14
Rome 13
Brooklyn 12
Jakarta 12
Montreal 12
Poplar 12
Phoenix 11
Southend 11
Warsaw 11
Frankfurt am Main 10
Jacksonville 10
Lappeenranta 10
Abuja 9
Atlanta 9
Houston 8
Paris 8
Ancona 7
Ann Arbor 7
Boston 7
Brussels 7
Chicago 7
Denver 7
Figino 7
Hải Dương 7
Amsterdam 6
Brasília 6
Chennai 6
Guangzhou 6
Tashkent 6
Turin 6
Vienna 6
Bonndorf 5
Da Nang 5
Haiphong 5
Hangzhou 5
Mexico City 5
Toronto 5
Washington 5
Baghdad 4
Bexley 4
Biên Hòa 4
Calgary 4
Charlotte 4
Dhaka 4
Fairfield 4
Johannesburg 4
Norwalk 4
Padova 4
Peschiera del Garda 4
Querétaro 4
San Francisco 4
Shanghai 4
Stockholm 4
Tianjin 4
Woodbridge 4
Amman 3
Ankara 3
Asunción 3
Baku 3
Bari 3
Campinas 3
Can Tho 3
Caracas 3
Totale 3.553
Salva come PNG Salva come JPEG
Nome #
Bile Acids Quantification by Liquid Chromatography-Tandem Mass Spectrometry: Method Validation, Reference Range, and Interference Study 206
Clinical assessment of FREND COVID-19 Ag test in an unselected population referred for routine SARS-CoV-2 testing 195
Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers 184
Reliability of a single-nostril nasopharyngeal swab for diagnosing SARS-CoV-2 infection 172
Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA 172
Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination 170
Analytical evaluation of the novel Mindray high sensitivity cardiac troponin I immunoassay on CL-1200i 163
Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series 159
Clinical Assessment of the DiaSorin LIAISON SARS-CoV-2 Ag Chemiluminescence Immunoassay 158
Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers 156
Preliminary evaluation of Roche Cobas Elecsys Anti-SARS-CoV-2 chemiluminescence immunoassay 152
Thrombin Generation in Patients with Coronavirus Disease 2019 149
Assessment of humoral and cellular immunity after bivalent BNT162b2 vaccination and potential association with reactogenicity 148
Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals 148
The pronounced decline of anti-SARS-CoV-2 spike trimeric IgG and RBD IgG in baseline seronegative individuals six months after BNT162b2 vaccination is consistent with the need for vaccine boosters 145
Real-world assessment of Fluorecare SARS-CoV-2 Spike Protein Test Kit 143
Monitoring of the immunogenic response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers with Snibe SARS-CoV-2 S-RBD IgG chemiluminescent immunoassay 140
Clinical performance of the Roche Elecsys SARS-CoV-2 antigen fully automated electrochemiluminescence immunoassay 138
Performance of Fujirebio Espline SARS-CoV-2 rapid antigen test for identifying potentially infectious individuals 136
Comparative longitudinal variation of total IgG and IgA anti-SARS-CoV-2 antibodies in recipients of BNT162b2 vaccination 132
Association between viral load and positivization time of a SARS-CoV-2 rapid antigen test in routine nasopharyngeal specimens 130
Clinical assessment of SNIBE Maglumi SARS-CoV-2 antigen fully-automated chemiluminescent immunoassay 130
SARS-CoV-2 Omicron infection is associated with high nasopharyngeal viral load 130
Are anti-SARS-CoV-2 S/N IgG/IgM antibodies always predictive of previous SARS-CoV-2 infection? 122
Accuracy of screening for hemolysis in plasma samples using a commercial urine dipstick 120
Clinical performance of Fujirebio Lumipulse G SARSCoV- 2 Ag chemiluminescent immunoassay 118
Monoclonal gammopathy in SARS-CoV-2 infection 115
Correlation Between Time to Positive Result of SARS-CoV-2 Rapid Antigen Self-Test and Viral Antigen Concentration 114
Longitudinal monitoring of anti-SARS-CoV-2 RBD IgG antibodies after BNT162b2 vaccination in healthcare workers 114
Humoral response post-BNT162b2 single booster in pre-vaccination baseline SARS-CoV-2 seronegative and seropositive subjects 113
Impact of the COVID-19 pandemic on the volume of laboratory testing 113
Cellular immunity against SARS-CoV-2 depends on the serological status 111
Evaluation of the acceptability of proposed hemolysis limits for Werfen ACL-TOP 750 CTS 104
Positivization time of a COVID-19 rapid antigen self-test predicts SARS-CoV-2 viral load: a proof of concept 103
Cost-effectiveness analysis of different COVID-19 screening strategies based on rapid or laboratory-based SARS-CoV-2 antigen testing 101
Serum C reactive protein predicts humoral response after BNT162b2 booster administration 100
Can cellular and humoral immunity predict response to BNT162b2 bivalent booster? 99
Three-month ad interim analysis of total anti-SARS-CoV-2 antibodies in healthy recipient of a single BNT162b2 vaccine booster 98
Impact of water temperature on reconstitution of quality controls for routine hemostasis testing 95
Machine learning model comparison in the screening of cholangiocarcinoma using plasma bile acids profiles 90
Real-world assessment of the clinical performance of COVID-VIRO ALL IN rapid SARS-CoV-2 antigen test 86
Early kinetics of cellular immunity in recipients of bivalent BNT162b2 vaccine: a proof-of-concept study 83
Serum levels of prostate specific antigen (PSA) after primary vaccination with BNT162b2 75
Monitoring humoral and cellular immunity over 6 months after mRNA-based bivalent COVID-19 vaccine administration 71
Vaccination time does not influence total anti-SARS-CoV-2 antibodies response 70
Variation of Total Anti-SARS-CoV-2 Antibodies After Primary BNT162b2 Vaccination and Homologous Booster 69
Impact of BNT162b2 primary vaccination and homologous booster on anti-SARS-CoV-2 IgA antibodies in baseline seronegative healthcare workers 68
Total anti-SARS-CoV-2 antibodies measured 6 months after Pfizer-BioNTech COVID-19 vaccination in healthcare workers 64
Impacto de la vacunación primaria con BNT162b2 y una dosis de refuerzo homóloga en los anticuerpos IgA contra SARS-CoV-2 en profesionales sanitarios seronegativos 7
Niveles séricos de antígeno prostático específico (PSA) tras vacunación primaria con BNT162b2 6
Variación longitudinal comparativa de los anticuerpos totales, IgG e IgA contra el SARS-CoV-2 en receptores de la vacuna BNT162b2 6
Son los anticuerpos IgG e IgM contra los antígenos S y N del SARS-CoV-2 siempre predictores de infección previa por SARS-CoV-2? 5
Totale 5.996
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.369
article - articoli 23.994
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 375
Totale 48.738
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022197 0 44 7 9 12 7 5 7 17 7 27 55
2022/2023659 37 55 58 120 37 138 23 59 67 9 30 26
2023/2024408 20 30 19 46 61 50 44 64 3 22 39 10
2024/20251.091 59 72 41 165 54 55 34 58 135 98 131 189
2025/20263.323 220 189 275 504 811 212 331 181 215 148 125 112
2026/2027202 23 179 0 0 0 0 0 0 0 0 0 0
Totale 5.996